Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma

NCT07332507 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07332507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
March 26, 2027
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent plasmablastic lymphoma, refractory plasmablastic lymphoma